XOMA Royalty Corp.
NASDAQ:XOMABiotechnology
+$0.19 today
- Market cap
- $503.77M
- Beta
- 0.87
- P/E (TTM)
- 15.8
- EPS (TTM)
- $2.65
Volume 4.22M
Average 0.21M
XOMA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
XOMA Royalty Corp.NASDAQ: XOMA
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $325K, compared with -$3.71M a year earlier. Trailing-twelve-month accounts receivables was $1.6M.
Context
- Accounts receivables amounted to 4.7% of revenue in FY2025, up 1.7 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $325K or moves back toward the trailing-twelve-month quarterly average of $401K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.43M) USD
- Year-over-year change
- -190.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.43M) | -190.5% |
| FY2024 | 2024-12-31 | (835K) | +16.7% |
| FY2023 | 2023-12-31 | (1M) | -582.2% |
| FY2022 | 2022-12-31 | 208K | -86.8% |
| FY2021 | 2021-12-31 | 1.58M | — |
Accounts Receivables vs competitors
How XOMA compares with its peers on the latest reported figures
- XOMA's LTM Mar 2026 accounts receivables of $1.6M is the 2nd largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +128.9% is the 2nd highest of 5, against a peer median of -51.3%.
- Accounts receivables amounts to 4.4% of revenue for XOMA, versus a peer median of 25.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.46M | -6.1% | — | 14.5% | |
| LTM Mar 2026 | $1.6M | +128.9% | — | 4.4% | |
| LTM Mar 2026 | $683K | +174.7% | — | 36.9% | |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| LTM Mar 2026 | $8.07K | -96.4% | +481.9% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding XOMA) | $0 | -51.3% | +481.9% | 25.7% | |
Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.8M | (17.1M) | (40.83M) | (13.82M) | 31.71M |
| Depreciation & Amortization | 7K | 104K | 900K | 216K | 2.97M |
| Deferred Income Tax | 0 | 0 | 0 | (5.66M) | 103K |
| Stock-Based Compensation | 6.2M | 3.61M | 9.1M | 10.31M | 9.27M |
| Change in Working Capital | (886K) | (181K) | (3.53M) | (2.79M) | (11.37M) |
| Accounts Receivables | 1.58M | 208K | (1M) | (835K) | (2.43M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 765K | 1.85M | (523K) | 1.6M | (10.6M) |
| Other Working Capital | (3.23M) | (2.23M) | (2M) | (3.55M) | 1.65M |
| Other Non-Cash Items | 1.56M | 694K | 16.2M | (2.01M) | (29.82M) |
| Operating Cash Flow | 22.68M | (12.88M) | (18.16M) | (13.75M) | 2.87M |
| Capital Expenditures | (26.5M) | (15.25M) | (17K) | (20K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (1.25M) | 3.85M |
| Purchases of Investments | 0 | 0 | 0 | (3.24M) | (99K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (26.5M) | (4.97M) | (694K) | (23.75M) | 47.14M |
| Investing Cash Flow | (26.5M) | (20.22M) | (711K) | (28.26M) | 50.89M |
| Debt Repayment | (4.25M) | 0 | 130M | (6.9M) | (10.6M) |
| Common Stock Issued | 1.58M | 2.42M | 466K | 5.21M | 8.72M |
| Common Stock Repurchased | 0 | 0 | (148K) | (13K) | (16.04M) |
| Dividends Paid | (3.5M) | (5.47M) | (5.47M) | (5.47M) | (5.47M) |
| Other Financing Activities | (21M) | (1.4M) | (3.79M) | 1.26M | (3.07M) |
| Financing Cash Flow | 12.84M | (4.45M) | 120.59M | (11.13M) | (26.46M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.01M | (37.55M) | 101.72M | (53.13M) | 27.29M |
| Free Cash Flow | (3.82M) | (28.13M) | (18.18M) | (13.77M) | 2.87M |
XOMA Royalty Corp.
NASDAQ:XOMA
Intrinsic Alpha fair value
Locked
Current Price
$40.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.